Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03856632 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Liraglutide Effect in Atrial Fibrillation

Study acronym: LEAF
StatusActive, Not Recruiting
PhasePhase 4
Started2019-03-18
View on ClinicalTrials.gov ↗

Amendment history

2026-04-27
Study Status v11
Re-verified, no change to tracked fields
2026-01-28
Study Status v10
Primary completion date2025-12-31→2026-12-31
Completion date2025-12-31→2026-12-31
2025-03-17
Study Status v9
Primary completion date2024-12-31→2025-12-31
Completion date2024-12-31→2025-12-31
2024-03-26
Study Status v8
Re-verified, no change to tracked fields
2023-04-18
Recruiting→Active, Not Recruiting Study Status, Study Design, Contacts/Locations v7
Trial statusRecruiting→Active, Not Recruiting
Primary completion date2023-12-31→2024-12-31
Completion date2023-12-31→2024-12-31
Study sitesdetails revised at 1 of 1 site
Show 6 earlier versions
2022-04-28
Study Status v6
Primary completion date2021-12-31→2023-12-31
Completion date2022-12-31→2023-12-31
2021-05-03
Study Status v5
Re-verified, no change to tracked fields
2020-12-21
Study Status, Eligibility v4
Eligibility criteria+37 characters
Inclusion Criteria: Male and female, age 18 or older Persistent atrial fibrillationAF defined as continuous AF that is sustained beyond 7 days (or atrialAF fibrillationwith in which athe decision is made to cardiovert the patient prior tobefore 7 days of enrollment or Paroxysmal AF defined as recurrent AF (≥2 episodes). that terminates spontaneously within 7 days BMI ≥27 kg/m2 Patient wishes to undergo a catheter ablation procedure for the treatment of atrial fibrillation Receiving follow-up care at [...] he University of Miami Exclusion Criteria: Inability to sign an informed consent Patients with p [...] [...]
2020-06-17
2 amendments v2-v3
2 re-verifications since 2019-12-05, no change to tracked fields
2019-04-16
Study Status v1
Start dateestimated 2019-02-24→confirmed 2019-03-18
2019-02-26
Original filing
The goal (or purpose) of this study is to evaluate (study) a new way to stabilize (steady) the activity between the fat deposits surrounding the heart and the left atrium. To reduce the amount of EAT, this study will use a medication called Liraglutide. This medication is known to work on fat deposits and produce weight loss. The investigator is conducting this study to find out if Liraglutide will reduce the fat deposits surrounding the participant's heart, and stabilize (and perhaps reduce or eliminate) atrial fibrillation activity.
Trial Details
NCT Number NCT03856632
Lead Sponsor University of Miami
Conditions Atrial Fibrillation
Enrollment 60 participants
Start Date 2019-03-18
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-01